使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.
作者信息
Marcos Luis A, Leung Annie, Kirkman Laura, Wormser Gary P
机构信息
Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Stony Brook University, USA.
Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
出版信息
IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.
Abstract
Tafenoquine is a highly effective treatment for infections in animal models. An immunocompromised patient infected by a strain of that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.
摘要
他非诺喹是动物模型感染的高效治疗药物。一名免疫功能低下的患者感染了一种对阿奇霉素和阿托伐醌至少部分耐药的巴贝斯虫菌株，接受了他非诺喹治疗。应考虑开展使用他非诺喹治疗其他巴贝斯虫病患者的系统临床研究。
相似文献
1
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.
IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.
2
Tafenoquine for Relapsing Babesiosis: A Case Series.
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
3
Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine.
Clin Infect Dis. 2023 Feb 18;76(4):741-744. doi: 10.1093/cid/ciac473.
4
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.
Clin Infect Dis. 2010 Feb 1;50(3):381-6. doi: 10.1086/649859.
5
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
J Infect Dis. 2024 Jan 12;229(1):161-172. doi: 10.1093/infdis/jiad315.
6
Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.
J Infect Dis. 2022 Jan 18;225(2):238-242. doi: 10.1093/infdis/jiab537.
7
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.
8
Atovaquone in the treatment of Babesia microti infections in hamsters.
Am J Trop Med Hyg. 1996 Aug;55(2):219-22. doi: 10.4269/ajtmh.1996.55.219.
9
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
J Infect Dis. 2020 Aug 17;222(6):1027-1036. doi: 10.1093/infdis/jiaa195.
10
Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Infection in an Immunocompromised Patient.
Pathogens. 2022 Sep 15;11(9):1051. doi: 10.3390/pathogens11091051.
引用本文的文献
1
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate.
Elife. 2025 Jun 19;13:RP101128. doi: 10.7554/eLife.101128.
2
A propidium iodide-based screen of the "Bug Box" against reveals potent inhibitors.
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0003525. doi: 10.1128/aac.00035-25. Epub 2025 Jun 9.
3
New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.
Front Vet Sci. 2024 Aug 14;11:1459989. doi: 10.3389/fvets.2024.1459989. eCollection 2024.
4
Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.
AAPS PharmSciTech. 2024 Jul 9;25(6):157. doi: 10.1208/s12249-024-02861-3.
5
Recent advances, challenges and updates on the development of therapeutics for malaria.
EXCLI J. 2024 May 6;23:672-713. doi: 10.17179/excli2023-6856. eCollection 2024.
6
Tafenoquine for Relapsing Babesiosis: A Case Series.
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
7
Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.
ACS Infect Dis. 2024 Apr 12;10(4):1405-1413. doi: 10.1021/acsinfecdis.4c00143. Epub 2024 Apr 2.
8
Immune Mediators Important for a Protective Secondary Response to .
Pathogens. 2024 Jan 28;13(2):123. doi: 10.3390/pathogens13020123.
9
Comparative chemical genomics in species identifies the alkaline phosphatase PhoD as a determinant of antiparasitic resistance.
Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2312987121. doi: 10.1073/pnas.2312987121. Epub 2024 Feb 20.
10
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
J Infect Dis. 2024 Jan 12;229(1):161-172. doi: 10.1093/infdis/jiad315.
本文引用的文献
1
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.
Clin Infect Dis. 2021 Jan 27;72(2):185-189. doi: 10.1093/cid/ciab050.
2
Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.
Parasit Vectors. 2020 Jul 20;13(1):362. doi: 10.1186/s13071-020-04235-7.
3
Serious Infectious Complications After Rituximab Therapy in Patients With Autoimmunity: Is This the Final Word?
Clin Infect Dis. 2021 Mar 1;72(5):738-742. doi: 10.1093/cid/ciaa131.
4
Tafenoquine (Arakoda; Krintafel) for malaria.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):101-104.
5
Tafenoquine: the new kid on the block.
Curr Opin Infect Dis. 2019 Oct;32(5):407-412. doi: 10.1097/QCO.0000000000000574.
6
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
J Infect Dis. 2019 Jul 2;220(3):442-447. doi: 10.1093/infdis/jiz119.
7
Approval of Tafenoquine for Malaria Chemoprophylaxis.
Am J Trop Med Hyg. 2019 Jun;100(6):1301-1304. doi: 10.4269/ajtmh.19-0001.
8
Tafenoquine - A Radical Improvement?
N Engl J Med. 2019 Jan 17;380(3):285-286. doi: 10.1056/NEJMe1816383.
9
Pharmaceutical Approval Update.
P T. 2018 Nov;43(11):659-661.
10
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.
Zotero 插件